中文 | English
Return
Total: 21 , 1/3
Show Home Prev Next End page: GO
Author:(Zehui YAN)

1.Adult zebrafish as a model organism for assessing the effects of hallucinogenic drugs on behaviors

Hui YAN ; Ruibin SU ; Zehui GONG

Chinese Pharmacological Bulletin 2014;(10):1464-1468

2.Clinical effects analyses of nedaplati or docetaxel combined with radiotherapy on patients with locally advanced uterine cervical cancer

Yan ZHANG ; Zehui SUN ; Zelin SUN

Clinical Medicine of China 2015;31(5):435-437

3.Endothelins system and myocardial hypertrophy

Linglei KONG ; Lingdi YAN ; Zehui GONG

Chinese Pharmacological Bulletin 2003;0(09):-

4.Expression of Cannabinoid receptor 2 in the CNS and pharmacology of its agonists

Suyan LI ; Lingdi YAN ; Zehui GONG

Chinese Pharmacological Bulletin 1987;0(01):-

5.Behavioral effects of early-life social isolation on adult rats

Shuling LI ; Hui YAN ; Zehui GONG

Military Medical Sciences 2014;(10):791-794,822

6.Current research progress in glutamate transporter subtype GLT-1 and its regulated drugs

Chengmin LI ; Hui YAN ; Zehui GONG

Chinese Pharmacological Bulletin 2003;0(10):-

7.The function of C-terminal tail of opioid receptors and the proteins interaction with C-terminal tail of opioid receptors

Peilan ZHOU ; Lingdi YAN ; Zehui GONG

Chinese Pharmacological Bulletin 2003;0(08):-

8.Effect of novel agonist of soluble guanylate cyclase sGC 003 on endothelin-1-induced cardiomyocyte hypertrophy

Ke LIU ; Lingdi YAN ; Zheng YONG ; Zehui GONG ; Ruibin SU

Chinese Journal of Pharmacology and Toxicology 2016;30(4):338-343

9.Value of combined CA125, CT and MRI in diagnosing the ovarian thecoma

Yan ZHANG ; Xiaoyuan QI ; Lixia WANG ; Zehui SUN

Clinical Medicine of China 2015;31(8):759-762

10.Primary investigation on heterodimerization of kappa-opioid receptor and ORL1 receptor.

Quan WEN ; Lingdi YAN ; Yulei LI ; Zehui GONG

Acta Pharmaceutica Sinica 2011;46(9):1078-83

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 21 , 1/3 Show Home Prev Next End page: GO